Alternatives to insulin aspart
FDA shortage status is active for insulin aspart; 2 same-class SPL records are listed below for registry comparison only.
Brand: NovoLog, Fiasp
insulin aspart class peers while FDA lists an active shortage
insulin aspart (NovoLog, Fiasp) is on an FDA shortage listing while 2 other Rapid-Acting Insulin SPL records remain in this registry peer set (class inventory 3). Labeled indication field for insulin aspart: NovoLog is used to improve blood sugar control in adults and children with diabetes.
Top FAERS reaction fields for insulin aspart total 33,322 reports across 10 reactions, set beside insulin glulisine, insulin lispro. Counts are exposure-weighted submissions, not per-patient risk.
About insulin aspart
NovoLog (insulin aspart) is a rapid-acting insulin that helps control blood sugar in people with diabetes. It works quickly to lower blood sugar levels after meals.
Used for: NovoLog is used to improve blood sugar control in adults and children with diabetes. Diabetes is a condition where your body doesn't make enough insulin or can't use insulin properly, leading to high blood sugar. This medicine helps to lower your blood sugar levels.
2 Rapid-Acting Insulin peers (wide set)
insulin glulisine
RxApidra
Apidra is used to improve blood sugar control in adults and children with diabetes. Diabetes is a condition where your body does not make enough insulin or cannot use insulin properly, leading to high blood sugar levels. This medicine helps to lower your blood sugar levels.
insulin lispro
RxHumalog
Admelog is used to improve blood sugar control in people with diabetes. Diabetes is a disease where your body does not make enough insulin or cannot use insulin properly. This medicine helps your body use sugar from the food you eat.
insulin aspart vs insulin glulisine & insulin lispro · FAERS reaction fields
FAERS top-reaction field "Blood Glucose Increased" shows the widest count spread between insulin aspart and insulin glulisine, insulin lispro in this extract (27,756-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | insulin aspart | insulin glulisine | insulin lispro |
|---|---|---|---|
| Blood Glucose Increased | 10,424 | 1,526 | 38,180 |
| Nausea | 3,724 | 370 | 4,787 |
| Blood Glucose Decreased | 3,344 | 445 | 8,761 |
| Fatigue | 2,664 | 297 | 3,754 |
| Dyspnoea | 2,553 | 383 | 3,081 |
| Diarrhoea | 2,542 | 279 | 3,156 |
| Vomiting | 2,387 | 335 | 3,121 |
| Dizziness | 2,013 | 401 | 2,924 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
insulin aspart shortage vs Rapid-Acting Insulin peer index
Shortage status
FDA shortage listing is active for insulin aspart (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for insulin aspart while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for insulin aspart: see also the generic vs brand label guide when reading NovoLog SPL strings.
Read our methodology - how this data is sourced, computed, and verified.